Foresight Diagnostics, an Aurora, CO-based developer of cancer detection tests, raised $58.75M in Series B funding.
The round was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. As part of this funding, Uplaksh Kumar, Ph.D., will be joining the Foresight Diagnostics board of directors.
The company intends to use the funds to accelerate the clinical development and commercialization of its cancer recurrence testing platform, PhasED-Seq.
Led by CEO Jake Chabon, Foresight Diagnostics is a cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and hematologic malignancies.